Protagonist Therapeutics (PTGX) Invested Capital (2018 - 2023)

Protagonist Therapeutics has reported Invested Capital for 6 years, with the latest figure at $10000.0 in Q2 2023.

• Quarterly Invested Capital fell 87.5% year-over-year to $10000.0 in Q2 2023, while the trailing twelve-month figure through Mar 2024 was $10000.0 (down 95.07% YoY) and the FY2022 annual result came in at $69000.0, down 92.32% from the prior year.
• Invested Capital fell to $10000.0 in Q2 2023 per PTGX's latest filing, from $22000.0 in the prior quarter.
• Over five years, Invested Capital peaked at $11.4 million in Q2 2021 and troughed at $10000.0 in Q2 2023.
• A 5-year average of $2.8 million and a median of $1.0 million in 2019 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2021 and 2022: Invested Capital soared 1036.19% in 2021, then plunged 99.3% in 2022.
• Over 5 years, Invested Capital stood at $10.0 million in 2019, then tumbled by 72.68% to $2.7 million in 2020, then sank by 67.09% to $899000.0 in 2021, then slumped by 92.32% to $69000.0 in 2022, then plunged by 85.51% to $10000.0 in 2023.
• According to Business Quant data, Invested Capital over the past three periods registered $10000.0, $22000.0, and $69000.0 for Q2 2023, Q1 2023, and Q4 2022 respectively.